Trial Profile
A Prospective, Multi-centre, Double-blind, Randomized Trial of Saroglitazar 4 mg versus Placebo in Patients With Non-Alcoholic Steatohepatitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Jan 2021
Price :
$35
*
At a glance
- Drugs Saroglitazar (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms EVIDENCES-III
- Sponsors Zydus Cadila
- 30 Dec 2020 Results published in the Zydus Cadila Media Release
- 14 Jan 2015 New trial record